American College of Radiology Appropriateness Criteria on Multiple Brain Metastases

Gregory M.M. Videtic; Laurie E. Gaspar; Amr M. Aref; Isabelle M. Germano; Brian J. Goldsmith; Joseph P. Imperato; Karen J. Marcus; Michael W. McDermott; Mark W. McDonald; Roy A. Patchell; H. Ian Robins; C. Leland Rogers; John H. Suh; Aaron H. Wolfson; Franz J. Wippold

doi:10.1016/j.ijrobp.2009.07.1720

American College of Radiology Appropriateness Criteria on Multiple Brain Metastases

Gregory M.M. Videtic, Laurie E. Gaspar, Amr M. Aref, Isabelle M. Germano, Brian J. Goldsmith, Joseph P. Imperato, Karen J. Marcus, Michael W. McDermott, Mark W. McDonald, Roy A. Patchell, H. Ian Robins, C. Leland Rogers, John H. Suh, Aaron H. Wolfson, Franz J. Wippold

Research output: Contribution to journal › Review article › peer-review

30 Scopus citations

Abstract

Whole-brain radiotherapy is an effective palliative treatment for patients with multiple brain metastases. Approximately half of these patients experience an improvement in their neurologic symptoms. However, a majority of them do not achieve local control and frequently die of progressive brain disease. Any perceived benefits from surgery need verification in prospective, randomized, Phase III clinical trials. The effectiveness of SRS for patients with multiple metastases may be primarily a function of proper patient selection, but it probably cannot replace the benefits of WBRT, as demonstrated in the Aoyama trial (34). Effective radiation sensitizers are needed because WBRT alone, even in doses of 5000-5440 cGy, has not been associated with an improved survival outcome. Future trials of WBRT must include prospective measurement of neurocognitive functioning before and after treatment as a standard component of the patient's assessment.

Original language	English
Pages (from-to)	961-965
Number of pages	5
Journal	International Journal of Radiation Oncology Biology Physics
Volume	75
Issue number	4
DOIs	https://doi.org/10.1016/j.ijrobp.2009.07.1720
State	Published - 15 Nov 2009

Keywords

Appropriateness criteria
Multiple brain metastases
Radiosurgery
Surgery
Whole-brain radiotherapy

Access to Document

10.1016/j.ijrobp.2009.07.1720

Cite this

Videtic, G. M. M., Gaspar, L. E., Aref, A. M., Germano, I. M., Goldsmith, B. J., Imperato, J. P., Marcus, K. J., McDermott, M. W., McDonald, M. W., Patchell, R. A., Robins, H. I., Rogers, C. L., Suh, J. H., Wolfson, A. H., & Wippold, F. J. (2009). American College of Radiology Appropriateness Criteria on Multiple Brain Metastases. International Journal of Radiation Oncology Biology Physics, 75(4), 961-965. https://doi.org/10.1016/j.ijrobp.2009.07.1720

@article{b007eedf58b34bc4b5276d2eaff964b5,

title = "American College of Radiology Appropriateness Criteria on Multiple Brain Metastases",

abstract = "Whole-brain radiotherapy is an effective palliative treatment for patients with multiple brain metastases. Approximately half of these patients experience an improvement in their neurologic symptoms. However, a majority of them do not achieve local control and frequently die of progressive brain disease. Any perceived benefits from surgery need verification in prospective, randomized, Phase III clinical trials. The effectiveness of SRS for patients with multiple metastases may be primarily a function of proper patient selection, but it probably cannot replace the benefits of WBRT, as demonstrated in the Aoyama trial (34). Effective radiation sensitizers are needed because WBRT alone, even in doses of 5000-5440 cGy, has not been associated with an improved survival outcome. Future trials of WBRT must include prospective measurement of neurocognitive functioning before and after treatment as a standard component of the patient's assessment.",

keywords = "Appropriateness criteria, Multiple brain metastases, Radiosurgery, Surgery, Whole-brain radiotherapy",

author = "Videtic, {Gregory M.M.} and Gaspar, {Laurie E.} and Aref, {Amr M.} and Germano, {Isabelle M.} and Goldsmith, {Brian J.} and Imperato, {Joseph P.} and Marcus, {Karen J.} and McDermott, {Michael W.} and McDonald, {Mark W.} and Patchell, {Roy A.} and Robins, {H. Ian} and Rogers, {C. Leland} and Suh, {John H.} and Wolfson, {Aaron H.} and Wippold, {Franz J.}",

year = "2009",

month = nov,

day = "15",

doi = "10.1016/j.ijrobp.2009.07.1720",

language = "English",

volume = "75",

pages = "961--965",

journal = "International Journal of Radiation Oncology Biology Physics",

issn = "0360-3016",

publisher = "Elsevier Inc.",

number = "4",

}

Videtic, GMM, Gaspar, LE, Aref, AM, Germano, IM, Goldsmith, BJ, Imperato, JP, Marcus, KJ, McDermott, MW, McDonald, MW, Patchell, RA, Robins, HI, Rogers, CL, Suh, JH, Wolfson, AH & Wippold, FJ 2009, 'American College of Radiology Appropriateness Criteria on Multiple Brain Metastases', International Journal of Radiation Oncology Biology Physics, vol. 75, no. 4, pp. 961-965. https://doi.org/10.1016/j.ijrobp.2009.07.1720

TY - JOUR

T1 - American College of Radiology Appropriateness Criteria on Multiple Brain Metastases

AU - Videtic, Gregory M.M.

AU - Gaspar, Laurie E.

AU - Aref, Amr M.

AU - Germano, Isabelle M.

AU - Goldsmith, Brian J.

AU - Imperato, Joseph P.

AU - Marcus, Karen J.

AU - McDermott, Michael W.

AU - McDonald, Mark W.

AU - Patchell, Roy A.

AU - Robins, H. Ian

AU - Rogers, C. Leland

AU - Suh, John H.

AU - Wolfson, Aaron H.

AU - Wippold, Franz J.

PY - 2009/11/15

Y1 - 2009/11/15

N2 - Whole-brain radiotherapy is an effective palliative treatment for patients with multiple brain metastases. Approximately half of these patients experience an improvement in their neurologic symptoms. However, a majority of them do not achieve local control and frequently die of progressive brain disease. Any perceived benefits from surgery need verification in prospective, randomized, Phase III clinical trials. The effectiveness of SRS for patients with multiple metastases may be primarily a function of proper patient selection, but it probably cannot replace the benefits of WBRT, as demonstrated in the Aoyama trial (34). Effective radiation sensitizers are needed because WBRT alone, even in doses of 5000-5440 cGy, has not been associated with an improved survival outcome. Future trials of WBRT must include prospective measurement of neurocognitive functioning before and after treatment as a standard component of the patient's assessment.

AB - Whole-brain radiotherapy is an effective palliative treatment for patients with multiple brain metastases. Approximately half of these patients experience an improvement in their neurologic symptoms. However, a majority of them do not achieve local control and frequently die of progressive brain disease. Any perceived benefits from surgery need verification in prospective, randomized, Phase III clinical trials. The effectiveness of SRS for patients with multiple metastases may be primarily a function of proper patient selection, but it probably cannot replace the benefits of WBRT, as demonstrated in the Aoyama trial (34). Effective radiation sensitizers are needed because WBRT alone, even in doses of 5000-5440 cGy, has not been associated with an improved survival outcome. Future trials of WBRT must include prospective measurement of neurocognitive functioning before and after treatment as a standard component of the patient's assessment.

KW - Appropriateness criteria

KW - Multiple brain metastases

KW - Radiosurgery

KW - Surgery

KW - Whole-brain radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=70449723680&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2009.07.1720

DO - 10.1016/j.ijrobp.2009.07.1720

M3 - Review article

C2 - 19857783

AN - SCOPUS:70449723680

SN - 0360-3016

VL - 75

SP - 961

EP - 965

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

IS - 4

ER -

American College of Radiology Appropriateness Criteria on Multiple Brain Metastases

Abstract

Keywords

Access to Document

Fingerprint

Cite this